B. Nixon

Development of peptides for targeting cell ablation agents concurrently to the Sertoli and Leydig cell populations of the testes: an approach to non-surgical sterilization

This study develops peptides to target and ablate Sertoli and Leydig cells in testes, aiming to create a non-surgical sterilization method for cats and dogs.

PI3K/mTOR is a therapeutically targetable genetic dependency in diffuse intrinsic pontine glioma

This study identifies PI3K/mTOR as a targetable genetic dependency in DIPG and demonstrates that combining paxalisib with metformin improves survival in xenograft models.

High-Throughput Global Phosphoproteomic Profiling Using Phospho Heavy-Labeled-Spiketide FAIMS Stepped-CV DDA (pHASED)

This paper introduces a new phosphoproteomics protocol, pHASED, which reduces sample preparation time and increases phosphoproteomic coverage compared to traditional methods, revealing potential therapeutic targets in AML.

Blockade of redox second messengers inhibits JAK/STAT and MEK/ERK signaling sensitizing FLT3-mutant acute myeloid leukemia to targeted therapies

This study identifies the Rac-NOX2 complex as a driver of redox signaling in FLT3-mutant AML, showing that inhibiting NOX2 reduces key signaling pathways and enhances response to FLT3 inhibitors.

IRF8 Governs Tumor-Associated Macrophage Control of T Cell Exhaustion

This study identifies IRF8 as a key factor in tumor-associated macrophages (TAMs) that induce T cell exhaustion by presenting cancer antigens, and shows its association with poor patient survival in renal cell carcinoma.

TGFβ Suppresses Type 2 Immunity to Cancer

This study shows that blocking TGFβ signaling in CD4+ T cells enhances type 2 immunity, promoting tumor healing and halting cancer progression through IL-4-mediated vasculature repair.